Letters to the Editor

Low-dose azacitidine, pioglitazone and all-trans retinoic acid is safe in patients aged ≥ 60 years with acute myeloid leukemia refractory to standard induction chemotherapy (AMLSG 26-16/AML-ViVA): results of the safety run-in phase

University Hospital Regensburg, Department of Internal Medicine III, Hematology and Oncology, Germany; Bavarian Center for Cancer Research, University Hospital Regensburg, Regensburg
University Hospital Regensburg, Department of Internal Medicine III, Hematology and Oncology, Germany; Division of Personalized Tumor Therapy, Fraunhofer Institute for Toxicology and Experimental Medicine, Regensburg
University Hospital Regensburg, Department of Internal Medicine III, Hematology and Oncology
University Hospital Regensburg, Department of Internal Medicine III, Hematology and Oncology
University Hospital Regensburg, Department of Internal Medicine III, Hematology and Oncology
Caritaskrankenhaus Lebach, Department of Hematology/Oncology
Klinikum Passau, Department Hematology and Oncology
Charite- University Medical Center Berlin- Department of Hematology, Oncology and Tumor Immunology, Campus Virchow-Klinikum, Berlin
Charite- University Medical Center Berlin- Department of Hematology, Oncology and Tumor Immunology, Campus Virchow-Klinikum, Berlin, Germany; University Hospital Ulm, Department of Internal Medicine III
National Center of Tumor Diseases Trial Center, German Cancer Research Center and Heidelberg University Hospital, Heidelberg, Germany; Heidelberg University Hospital, Department of Internal Medicine V, Heidelberg
University Hospital Ulm, Department of Internal Medicine III
University Hospital Ulm, Department of Internal Medicine III
Center for Clinical Studies, University Hospital Regensburg, Regensburg
University Hospital Ulm, Department of Internal Medicine III
University Hospital Regensburg, Department of Internal Medicine III, Hematology and Oncology
University Hospital Regensburg, Department of Internal Medicine III, Hematology and Oncology
University Hospital Regensburg, Department of Internal Medicine III, Hematology and Oncology, Germany; Leibniz Institute for Immunotherapy, Division of Genetic Immunotherapy, Regensburg
Haematologica Early view Oct 26, 2023 https://doi.org/10.3324/haematol.2023.283864